How Much Can Celgene’s Buyback Impact Its Growth?
Celgene announced that its board authorized the repurchase of up to an additional $4.0 billion of its common stock.
Health and Healthcare
All Health and Healthcare Articles
Newest first · Page 2624 Health Care Stocks That Are Very Likely Buyout Targets
In a new report, Stifel opines that the consolidation in the managed care organizations is not a matter of if, but just a question of when.
Could the Health Insurance Mergers Leave an Odd Man Out?
24/7 Wall St. cannot help but wonder if it is possible that one of these top health insurance companies could be left without a merger partner.
Is Sunesis Coming Back From the Dead?
ThinkstockSunesis Pharmaceuticals Inc. (NASDAQ: SNSS) was making moves as the week drew to a close. This company was part of the red-hot health care sector, but it really did not gain any benefit from…
Short Sellers Back Off Big Pharma
The May 29 short interest data have been compared with the previous figures, and for most of the selected pharmaceutical stocks, short interest is down.
Short Sellers Lose Some Conviction Against Big Biotech
The May 29 short interest data have been compared with the previous figures, and for most of the selected biotech stocks, short interest has decreased.
Why MannKind Could Be an Endless Tug-of-War Stock
MannKind remains one of the biggest battleground stocks out there in the realm of biotech and emerging pharmacueticals.
Is the Teva and Mylan Merger Fight Going to Turn Away Shareholders?
ThinkstockTeva Pharmaceutical Industries Ltd. (NYSE: TEVA) is trying to transform itself by making its generics business even larger if it can pull off its desire to acquire Mylan N.V. (NASDAQ: MYL). The deal would…
Autoimmune Drugs to Drive Big Pharma Higher in Coming Years
Credit Suisse has updated its autoimmune market model and it sees implications for all of the large cap U.S. pharmaceutical companies in its coverage.
Events and Presentations Shake Out MannKind Short Sellers
After finally getting FDA clearance for the inhalable insulin Afrezza, and after a very slow start to the diabetes market, MannKind shares have now nearly doubled from their 52-week low.
New Mega-Blockbuster Cholesterol Drug Class Faces Make-or-Break FDA Panels
This coming week is likely to be a serious one in the fight against cholesterol. FDA panels are evaluating more than just one drug candidate.
How 6 ASCO Biotech Winners Are Focusing on the Future of Cancer
24/7 Wall St. has taken a look at some of the major ASCO winners over the past week and how they have performed since before the ASCO news.
Tivozanib Is the Gift That Keeps on Giving for Aveo
ThinkstockAveo Pharmaceuticals Inc. (NASDAQ: AVEO) has been on a roller coaster for the past few months. Previously Aveo made a 50% run in May after it released details regarding its study of renal cell…
Has Rite Aid’s Turnaround Already Peaked?
Some companies like to keep their investors updated on a month-to-month basis, tracking their sales. News from this can go one of two ways for the stock.
Why Opko’s Acquisition Will Transform Its Future Growth
Bio-Reference Laboratories and Opko Health announced Thursday morning that they have a definitive merger agreement in which the latter will acquire the former.